Gary D Kao

US Patent:

8541476, Sep 24, 2013

Filed:

Sep 12, 2008

Appl. No.:

12/677478

Inventors:

Constantinos Koumenis - Philadelphia PA, US
Brian E. Lally - Miami FL, US
Steven Kridel - Clemmons NC, US
Gary D. Kao - Wynnewood PA, US
Adeboye Adejare - Mantua NJ, US

Assignee:

The Trustees of the University of Pennsylvania - Philadelphia PA
Wake Forest University Health Sciences - Winston-Salem NC
University of the Sciences in Philadelphia - Philadelphia PA

International Classification:

A61K 31/10
C07C 315/00
C40B 30/06

US Classification:

514709

Abstract:

The present invention comprises compounds, compositions and methods of use for sensitizing cancer cells, tumors, neoplasms, and malignancies to the effects of ionizing radiation used in the treatment of cancer. The invention further comprises a method of identifying novel radiosensitizing compounds.

US Patent:

20060024694, Feb 2, 2006

Filed:

Mar 30, 2005

Appl. No.:

11/093692

Inventors:

Rene Daniel - Ambler PA, US
Anna Skalka - Princeton NJ, US
Gary Kao - Wynnewood PA, US
Giuseppi Nunnari - Cantania, IT
Roger Pomerantz - Chalfont PA, US

International Classification:

C12Q 1/68
G01N 33/53

US Classification:

435006000, 435007100

Abstract:

Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.

US Patent:

20110086423, Apr 14, 2011

Filed:

Jun 14, 2010

Appl. No.:

12/815125

Inventors:

Rene Daniel - Ambler PA, US
Anna Marie Skalka - Princeton NJ, US
Gary D. Kao - Wynnewood PA, US
Giuseppe Nunnari - Cantania, IT
Roger J. Pomerantz - Chalfont PA, US

International Classification:

C12N 5/071

US Classification:

435366, 435325

Abstract:

Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.

US Patent:

20210062273, Mar 4, 2021

Filed:

Aug 25, 2020

Appl. No.:

17/002145

Inventors:

- Philadelphia PA, US
Jay F. Dorsey - Media PA, US
Gary D. Kao - Wynnewood PA, US
Donald O'Rourke - Wynnewood PA, US

International Classification:

C12Q 1/6886

Abstract:

Provided herein are methods and compositions for detecting EGFR amplification and the presence of EGFR variants in a biological sample.

US Patent:

20180113130, Apr 26, 2018

Filed:

Nov 14, 2017

Appl. No.:

15/812105

Inventors:

- Philadelphia PA, US
Jay F. Dorsey - Media PA, US
Gary D. Kao - Wynnewood PA, US
Emigdio Reyes - Philadelphia PA, US

International Classification:

G01N 33/574
B01L 3/00
C12Q 1/6897
G01N 33/543

Abstract:

A repeatable method for detecting circulating tumor cells in vitro is provided. The method involves combining a test sample from a patient suspected of having circulating tumor cells, and a non-lytic adenoviral system, and culture media for the cells. The adenoviral system utilizes (i) a first replication-defective adenoviral particle in which an expression cassette is packaged, said expression cassette comprising an adenoviral 5′ and 3′ ITRs and a tumor-specific promoter; and (ii) a coding sequence for a reporter protein which is expressed in the presence of circulating tumor cells, and an adenoviral 3′ ITR. The test sample and the non-lytic adenoviral system are incubated for a sufficient time to permit expression of the reporter protein, and measuring reporter protein expression in the test samples, whereby presence of reporter expression indicates the presence of circulating tumor cells in the sample. Because the system is non-lytic, the testing can be repeated on the cells which remain viable in culture. Also provided is a method for enriching test samples having circulating tumor cells and a microfluidics device suitable for CTC-specification identification and enumeration.

US Patent:

20170298454, Oct 19, 2017

Filed:

Oct 5, 2015

Appl. No.:

15/517143

Inventors:

- Philadelphia PA, US
Gary D. Kao - Wynnewood PA, US
Stephen M. Hahn - Glen Mills PA, US

International Classification:

C12Q 1/68

Abstract:

A method useful for identifying and isolating live circulating tumor cells is described. The method utilizes an adenoviral vector comprising a replication-competent adenovirus in which the E1 gene region is expressed under the control of a telomerase-specific promoter and further comprises a second expression cassette containing a marker protein, optionally fused to a detectable cell surface marker to permit detection of circulating tumor cells lacking cell surface markers. The method involves combining ex vivo a test sample from a patient suspected of having circulating tumor cells, an adenoviral probe system, and culture media for the cells. The test sample is incubated with the adenoviral system for a sufficient time to permit expression of the reporter protein. The marker gene expression can thereafter be quantitated and the marker-expressing cells may optionally be collected for further analysis.

US Patent:

20150285786, Oct 8, 2015

Filed:

Mar 14, 2013

Appl. No.:

14/438321

Inventors:

- Philadelphia PA, US
Jay F. Dorsey - Media PA, US
Gary D. Kao - Wynnewood PA, US
Emigdio Reyes - Philadelphia PA, US

International Classification:

G01N 33/50

Abstract:

A repeatable method for detecting circulating tumor cells in vitro is provided. The method involves combining a test sample from a patient suspected of having circulating tumor cells, and a non-lytic adenoviral system, and culture media for the cells. The adenoviral system utilizes (i) a first replication-defective adenoviral particle in which an expression cassette is packaged, said expression cassette comprising an adenoviral 5′ and 3′ ITRs and a tumor-specific promoter; and (ii) a coding sequence for a reporter protein which is expressed in the presence of circulating tumor cells, and an adenoviral 3′ ITR. The test sample and the non-lytic adenoviral system are incubated for a sufficient time to permit expression of the reporter protein, and measuring reporter protein expression in the test samples, whereby presence of reporter expression indicates the presence of circulating tumor cells in the sample.